RAS Mutations Enhance Chemotherapy in AML

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 17 No 7
Volume 17
Issue 7

Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission.

Among 185 patients with acute myeloid leukemia, 34 had RAS mutations and 22 received high-dose cytarabine after complete remission. Their relapse rate was 45%, compared with 68% for high-dose patients with normal RAS, according to a CALGB study published online (JCO June 16, 2008). This could allow doctors to identify patients who would benefit from aggressive therapy.

Recent Videos
2 KOLs are featured in this series.
2 KOLs are featured in this series.
Experts highlight methods for optimally treating patients with genitourinary cancers harboring variant histologies at World GU 2025.
Generally, the communication in academic oncology institutions is favorable; however, when oncologists and pathologists become busy, specimens may be sent to reference laboratories.
Related Content